Literature DB >> 2826358

Retrobulbar neuritis as the first sign of the glucagonoma syndrome.

E R Lambrecht1, T L van der Loos, A H van der Eerden.   

Abstract

A 63-year-old man with a metastasising pancreatic glucagonoma is described, who presented with progressive deterioration of vision and bilateral central scotomata as the first symptom. This patient was treated with dacarbazine (DTIC) 250 mg/m2 IV daily for five consecutive days at 4-week intervals. The vision returned completely to normal, in a clinical and biochemical remission. Although there is no wide experience in treatment, the literature seems to indicate that DTIC should be the drug of choice in treating metastatic glucagonoma. Central scotomata may be a new 'paraneoplastic' symptom and a key to the earlier diagnosis of the glucagonoma syndrome by ophthalmologists, just as necrolytic migratory erythema has been for the dermatologists.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2826358     DOI: 10.1007/BF02027892

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  13 in total

1.  The glucagonoma syndrome and its management.

Authors:  A Kessinger; H M Lemon; J F Foley
Journal:  J Surg Oncol       Date:  1977       Impact factor: 3.454

2.  Necrolytic migratory erythema with pancreatic carcinoma.

Authors:  D S Wilkinson
Journal:  Proc R Soc Med       Date:  1971-12

3.  Successful treatment of metastatic glucagonoma with dacarbazine.

Authors:  T Kurose; Y Seino; H Ishida; J Fujita; T Taminato; M Matsukura; H Imura
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

4.  The glucagonoma syndrome.

Authors:  J H Paulusma-de Waal; F T Bosman; H R Fischer; P C Van der Velden; W H Hackeng
Journal:  Neth J Med       Date:  1982       Impact factor: 1.422

5.  Dimethyltriazenoimidazole carboxamide therapy of malignant glucagonoma.

Authors:  G M Strauss; S A Weitzman; T T Aoki
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

6.  Glucagonoma syndrome. A clinicopathologic, immunocytochemical, and ultrastructural study.

Authors:  P R Vandersteen; B W Scheithauer
Journal:  J Am Acad Dermatol       Date:  1985-06       Impact factor: 11.527

7.  Neurologic involvement in glucagonoma syndrome: response to combination chemotherapy with 5-fluorouracil and streptozotocin.

Authors:  J D Khandekar; D Oyer; H J Miller; N A Vick
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

8.  Therapy of malignant APUD cell tumors. Effectiveness of DTIC.

Authors:  A Kessinger; J F Foley; H M Lemon
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

9.  Clinical aspects of glucagon-producing islet cell tumors.

Authors:  R A Prinz; T R Dorsch; A M Lawrence
Journal:  Am J Gastroenterol       Date:  1981-08       Impact factor: 10.864

10.  Operative and chemotherapeutic management of malignant glucagon-producing tumors.

Authors:  R A Prinz; K Badrinath; M Banerji; M Sparagana; T R Dorsch; A M Lawrence
Journal:  Surgery       Date:  1981-10       Impact factor: 3.982

View more
  1 in total

Review 1.  A review of the therapy of paraneoplastic neurologic syndromes.

Authors:  A Das; F H Hochberg; S McNelis
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.